Innorna secures dual FDA designations for Wilson’s disease mRNA therapy
Innorna could receive a priority review voucher if its asset IN013 is approved by the FDA.
Trilink Thematic mRNA WP
Ethris and Lonza to develop mRNA vaccines for respiratory conditions
FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
FDA approves IND application for Everest’s cancer vaccine
MHRA seeks input on new regulatory guidance for cancer vaccines
HHS awards $590m to Moderna for mRNA ‘flu vax development
Moderna’s mRESVIA vaccine gains Health Canada approval
mRNA licensing agreements surge 800% amid GSK lawsuits
